Your Article Summary
See Latest ArticlesBiologics dont need long market exclusivity, FTC says
American Medical News , 06/30/09
Trapp D - A recent Federal Trade Commission report asserting that original biopharmaceutical drug manufacturers do not need lengthy exclusive marketing periods to maintain innovation has not driven supporters from a bill that would extend such protection.
Related Articles
Nabi Biopharmaceuticals to Hold Conference Call
Nabi Biopharmaceuticals, 11/17/09
Relevance Score: 87%
Bristol-Myers Squibb and Alder Biopharmaceuticals Enter Global Agreement on Rheumatoid Arthritis Biologic
Bristol Myers-Squibb Company, 11/11/09
Relevance Score: 84%
Nabi Biopharmaceuticals Participates in NicVAX(R) Phase IIb Study
Nabi Biopharmaceuticals, 10/29/09
Relevance Score: 84%
Nabi Biopharmaceuticals to Announce Third Quarter Financial Results on November 2009
Nabi Biopharmaceuticals, 10/28/09
Relevance Score: 84%
Sanofi-aventis to acquire FOVEA, a French biopharmaceutical ophthalmology company
Sanofi-aventis, 10/02/09
Relevance Score: 84%
Today in Biotechnology...keeping you current
Receive free subspecialty "5-minute updates" via email
Quality by Design for Biotechnology Products—Part 2
BioPharm, 12/09/09
Amylin Pharmaceuticals to Present at the 2009 Deutsche Bank Biotech Boston Confab
Amylin Pharmaceuticals, 12/09/09
PR distribution service for the biotech industry
b3c newswire, 12/07/09